GlassScriptPhysician profile
Stuart Alex Brill
NPI 1063998268
$1,563.64
in general payments reported to CMS, 2019-2025
23 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $11.60 · 2021: $40.60 · 2022: $221 · 2023: $250 · 2024: $332 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $609.16 | 2019-2025 | Briviact |
| Alnylam Pharmaceuticals INC. | $155.88 | 2019 | |
| Mdd US Operations, LLC | $137.16 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $112.80 | 2022-2023 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $68.04 | 2019 | |
| Csl Behring | $65.33 | 2019-2023 | Hizentra |
| Microvention, INC. | $39.76 | 2023 | Web Aneurysm Embolization System |
| Avanir Pharmaceuticals, INC. | $35.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.59 | 2022 | |
| Merck Sharp & Dohme LLC | $31.13 | 2023-2024 | Verquvo, Dificid, Zerbaxa |
| Vertical Pharmaceuticals, LLC | $31.04 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $28.68 | 2021 | |
| Stryker Corporation | $27.66 | 2023 | Surpass Evolve |
| Lilly USA, LLC | $27.57 | 2022 | |
| Genzyme Corporation | $25.84 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $22.46 | 2022 | |
| Amgen INC. | $20.65 | 2019 | |
| Argenx US, INC. | $18.02 | 2023 | Vyvgart |
| Teva Pharmaceuticals USA, INC. | $16.14 | 2023 | Austedo |
| Biohaven Pharmaceutical Holding Company LTD. | $15.47 | 2022 | |
| Acadia Pharmaceuticals INC | $15.30 | 2019 | |
| Aquestive Therapeutics, INC. | $15.19 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Brill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.